Phase II evaluation of nanoparticle albumin-bound paclitaxel in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer

Journal of Clinical Oncology

Volumn 27, Issue 9, 2009, Pages 1426-1431

  Teneriello, Michael G ^a   Tseng, Paul C ^a   Crozier, Mark ^a   Encarnacion, Carlos ^a   Hancock, Kenneth ^a   Messing, Mark J ^a   Boehm, Kristi A ^a   Williams, Alicia ^a   Asmar, Lina ^a  

^a Developmental Therapeutics Committee and Co Chair of the Genitourinary Committee   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CA 125 ANTIGEN; DOCETAXEL; NANOPARTICLE; NANOPARTICLE ALBUMIN BOUND PACLITAXEL; PACLITAXEL; PLATINUM; UNCLASSIFIED DRUG; 130 NM ALBUMIN BOUND PACLITAXEL; 130-NM ALBUMIN-BOUND PACLITAXEL; ALBUMINOID; ANTINEOPLASTIC AGENT;

ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EVALUATION; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PERITONEUM CANCER; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENT CANCER; TREATMENT RESPONSE; UPPER RESPIRATORY TRACT INFECTION; UTERINE TUBE CARCINOMA; MIDDLE AGED; MULTICENTER STUDY; OVARY TUMOR; PERITONEUM TUMOR; QUALITY OF LIFE; TUMOR RECURRENCE; UTERINE TUBE TUMOR;

ADULT; AGED; AGED, 80 AND OVER; ALBUMINS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PACLITAXEL; PERITONEAL NEOPLASMS; QUALITY OF LIFE;

EID: 63049085227     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.18.9548     Document Type: Article

References (23)

1. American Cancer Society: What are the key statistics for ovarian cancer? http://www.cancer.org/docroot/CRI/content/CRI-2-4-1X-What-are-the-key- statistics-for-ovarian-cancer-33.asp?sitearea=
2. American Cancer Society: What is ovarian cancer? http://www.cancer.org/ docroot/CRI/content/CRI-2-4-1X-What-is-ovarian-cancer-33.asp?rnav=cri
3. Eltabbakh GH, Werness BA, Piver S, et al: Prognostic factors in extraovarian primary peritoneal carcinoma. Gynecol Oncol 71:230-239, 1998
4. Ozols RF, Bundy BN, Greer BE, et al: Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: A Gynecologic Oncology Group study. J Clin Oncol 21:3194-3200, 2003
5. Vasey PA, Jayson GC, Gordon A, et al: Scottish Gynaecological Cancer Trials Group: Phase III randomized trial of docetaxel-carboplatin versus paclitaxelcarboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682-1691, 2004
6. Armstrong DK, Bundy B, Wenzel L, et al: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 354:34-43, 2006
7. Gadducci A, Cosio S, Fanucchi A, et al: The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based cenmotherapy in patients with advanced ovarian carcinoma. Gynecol Oncol 93:131-136, 2004
8. Balbi GC, Cardone A, Passaro M, et al: Comparative evaluation of standard criteria and CA-125 in ovarian cancers treated with platinum or paclitaxel. Eur J Gynaecol Oncol 26:285-287, 2005
9. Papadimitriou CA, Fountzilas G, Aravantinos G, et al: Second-line chemotherapy with gemcitabine and carboplatin in paclitaxel-pretreated, platinum-sensitive ovarian cancer patients: A Hellenic Cooperative Oncology Group Study. Gynecol Oncol 92:152-159, 2004
10. Kose MF, Sufliarsky J, Beslija S, et al: A phase II study of gemcitabine plus carboplatin in platinumsensitive, recurrent ovarian carcinoma. Gynecol Oncol 96:374-380, 2005
11. Strauss HG, Henze A, Teichmann A, et al: Phase II trial of docetaxel and carboplatin in recurrent platinum-sensitive ovarian, peritoneal and tubal cancer. Gynecol Oncol 104:612-616, 2007
12. Desai N, Trieu V, Yao Z, et al: Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophorfree, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res 12:1317-1324, 2006
13. Blum JL, Savin MA, Edelman G, et al: Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 7:850-856, 2007
14. Rizvi NA, Riely GJ, Azzoli CG, et al: Phase I/II trial of weekly intravenous 130-nm albumin-bound paclitaxel as initial chemotherapy in patients with stage IV non-small-cell lung cancer. J Clin Oncol 26:639-643, 2008
15. Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92:205-216, 2000
16. National Cancer Institute: Common Terminology Criteria for Adverse Events version 3.0. (CTCAE). http://ctep.cancer.gov/reporting/ctc-v30.html
17. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
18. Functional Assessment of Chronic Illness Therapy: Ovarian specific questionnaire. http://www.facit.org/
19. Parmar MK, Ledermann JA, Colombo N, et al: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4/AGO-OVAR-2.2 trial. Lancet 361:2009-2106, 2003
20. Pfisterer J, Plante M, Vergote I, et al: Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: And intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol 24:4699-4707, 2006
21. Kavanagh J, Tresukosol D, Edwards C, et al: Carboplatin reinduction after taxane inpatients with platinum-refractory epithelial ovarian cancer. J Clin Oncol 13:1584-1588, 1995
22. Boruta DM 2nd, Fowler WC Jr, Gehrig PA, et al: Weekly paclitaxel infusion as salvage therapy in ovarian cancer. Cancer Invest 21:675-681, 2003
23. Omura GA, Brady MF, Look KY, et al: Phase III trial of paclitaxel at two dose levels, the higher dose accompanied by filgrastim at two dose levels in platinum-pretreated epithelial ovarian cancer: An intergroup study. J Clin Oncol 21:2843-2848, 2003